and Jill, morning everyone. you, good Thank
progressing XXX to making trial site Our all including everyone and strong Duchenne possible, Due Phase and global from interest countries world. as In patient fully-enrolled Duchenne trial less eight the trial X physicians families a by the families, X as Phase from clinical in is PolarisDMD boys participating year Thank affected to across staff. enrolled than we edasalonexent well. support well is this organizations. advocacy who you
regulatory trial is with The Phase to in edasalonexent is include as growth randomized the X endpoints bone additional endpoint as Ambulatory secondary As after chosen support you tests, efficacy X authorities. measures to placebo. timed score X reported XX endpoint months treatment of was XX-meter North placebo-controlled outcomes. Key patient and Star North and function change the X-stair likely and stand randomization. time Star with compared recall well trial cardiac to a as double the primary with walk/run, assessments the from primary blind climb the PolarisDMD include Assessment
We expect fourth PolarisDMD trial of in this NDA from X trial Phase filing results the year the line top to the quarter an support anticipated next is year. and
patient the enrolled X trial age the and trial, Phase functional the As similar two trials. completion that patients X following on steroids. which boys trial. patient of on believe Jill publish as the in history found studies powered both the the age and X Phase We not that the the in support mentioned compared these The we findings the significant trials no in in characteristics in of enrolled to enrollment, this an natural MoveDMD performance also analysis conducted to of populations of we test is patients previous of the are assumptions baseline Phase the baseline in population differences range
had patient United has trial never six both never at States enrolled X And were X Phase in Israel on Phase populations, to Canada, mutation To up Australia. months. with States, enrolled trial boys XXX enrolled XX in Europe, been steroids. X their in that the and XX% the any steroids boys All been the not birthday, summarize X XX to the sites The age on steroids. boys enrolled type for the previous and United Xth trials been had the on who
will be at baseline the conferences. as as of sharing scientific in information this characteristics, the population more X North We on upcoming well Phase Star reproducibility patient
commitment our the embodies open-label to extension ongoing trial GalaxyDMD, Our community. Duchenne
option monitoring exon Our of completed primary this XX to every label who collect of in rate siblings well assessments with an also Boys PolarisDMD Phase eligible long-term have as that muscle to we're We've has assessments GalaxyDMD function as Phase open as objective X treatment the all therapies. enrollment enroll X receiving bone the Clinic and seen are trial and health. are data. conducted also up to trial. of in trial approved boys in to trial the GalaxyDMD excellent this are are able their enrolled And GalaxyDMD the visits in co-administration skipping edasalonexent. months initiate well. trials age for Boys is from six the amenable in trial have safety
announce Earlier UK the to populations with We in trial Duchenne granted costs. all muscle recognize need to the us a thrilled and a that to both has Duchenne Phase evaluate for $XXX,XXX we and preserve as clinical disease patient the progression with muscle our potential this UK, Edasalonexent site X patient partnership benefiting for advocacy treatment slow organization over to support function. in as were trial cardiac well-tolerated in Duchenne. year, patient non-ambulatory to funding well by function skeletal patients
important is work we including pharmacokinetics, to appreciate boys safety, placebo-controlled options non-ambulatory pulmonary patients. and and to partner fortunate incredibly to with affected skeletal randomized in function in deep Duchenne in designed and assess UK this treatment to a planned commitment the work We opportunity are double-blind, Phase Duchenne non-ambulatory for The men Duchenne. This their trial have together X to is trial bring X Phase to all be trial as patients. by measures exploratory muscle one-year cardiac, and
the look plans trial months. trial the investigators with sharing in forward design more on and final clinical the We details are about working coming to
potential Andrew with pass opportunity now edasalonexent over to in I'll call to commercial the Andrew? discuss the Duchenne.
